A Phase II Study of the Combination of Oxaliplatin, Capecitabine, and Trastuzumab and Chemoradiotherapy in the Adjuvant Setting in Operated Patients With HER2-positive Gastric or Gastroesophageal Junction Cancer (TOXAG Study) A Turkish Oncology Group Study

Abali, Huseyin; YALÇIN, ŞUAYİB; Onal, Huseyin; Dane, Faysal; Oksuzoglu, Berna; ÖZDEMİR, NURİYE; Mertsoylu, Huseyin; ARTAÇ, MEHMET; Camci, Celaletdin; KARABULUT, BÜLENT; Basal, Fatma; Budakoglu, Burcin; Sendur, Mehmet; Goktas, Burce; Ozdener, Fatih; Baygul, Arzu

doi:10.1097/coc.0000000000000825

A Phase II Study of the Combination of Oxaliplatin, Capecitabine, and Trastuzumab and Chemoradiotherapy in the Adjuvant Setting in Operated Patients With HER2-positive Gastric or Gastroesophageal Junction Cancer (TOXAG Study) A Turkish Oncology Group Study

Copy For Citation

Abali H., YALÇIN Ş. , Onal H. C. , Dane F., Oksuzoglu B., ÖZDEMİR N., ...More

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, vol.44, no.7, pp.301-307, 2021 (Journal Indexed in SCI)

Publication Type: Article / Article
Volume: 44 Issue: 7
Publication Date: 2021
Doi Number: 10.1097/coc.0000000000000825
Title of Journal : AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
Page Numbers: pp.301-307

Abstract

Background: Trastuzumab prolonged the overall survival in patients with advanced gastric cancer with human epidermal growth factor receptor 2 (HER2) overexpression in combination with chemotherapy. In this phase II open-label prospective study, the tolerability and safety of trastuzumab with chemotherapy, and chemoradiotherapy for curatively resected patients with HER2-positive gastric carcinoma was investigated.